Tezacitabine

N/A

Report date: 2022/12/07 17:16:03
NME

Base Information

Drug NameTezacitabine
Drug Alias Nametezacitabinum替扎他滨tezacitabinaKW-2331FMdC +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRibonucleotide reductase inhibitorsDNA polymerase alpha subunit inhibitors
TargetsDNA polymerase alpha subunitRibonucleotide reductase
Therapy Area/IndicationsHematologic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChiron CoThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsHematologic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG